【摘要】 目的探讨肺癌原发灶和转移纵隔淋巴结中EGFR突变率有无差异。方法采用PCR扩增ARMS法,分析NSCLC原发灶组织中EGFR基因突变与纵隔转移淋巴结中EGFR基因突变情况,比较两者突变率。结果 37例非小细胞肺癌患者原发灶检测到EGFR基因突变,突变率为37%,34例纵隔转移淋巴结检测到EGFR基因突变,突变率为34%。NSLCL患者原发灶和纵隔转移淋巴结中EGFR均有突变95.77%;均没有突变97.67%。肺癌原发灶与纵隔淋巴结EGFR突变一致率达到97%。肺癌原发灶与纵隔淋巴结EGFR突变率比较无差异P>0.05。结论肺癌原发灶与纵隔转移淋巴结EGFR突变率无差异。更多还原

【Abstract】 Objective To investigate the difference in EGFR mutation rate between primary lung cancer and mediastinal metastasis lymph node.Methods PCR amplification ARMS method was used to analyze the EGFR gene mutations in tumor tissues of NSCLC and mediastinal metastasis lymph node,and the mutation rate was compared between the 2 groups.Results EGFR gene mutations were detected in 37 patients with NSCLC,the mutation rate was 37%,34 cases of mediastinal metastasis lymph node were detected EGFR gene mutation,the mutation rate was 34%.In NSCLC and mediastinal metastasis lymph node,EGFR all had mutations,95.77%; no mutations,97.67%.Primary lung cancer and mediastinal metastasis lymph node EGFR mutation rate reached 97.00%.There was no difference in EGFR mutation rate between primary tumor and mediastinal metastasis lymph node,P > 0.05.Conclusion Primary lung cancer and mediastinal metastasis lymph node EGFR mutation rates have no significant difference.更多还原